Share on Pinterest Researchers say brain lesions don’t appear to be connected to severe disability in multiple sclerosis. SeventyFour/Getty Images About 1 million people in the United States live with ...

"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...

Between 30 to 50 percent of people living with multiple sclerosis (MS) will experience memory problems but the cause is uncertain. Brain lesions are the hallmark imaging sign used to diagnose MS and ...

Between 30 to 50 percent of people living with multiple sclerosis (MS) will experience memory problems but the cause is uncertain. Brain lesions are the hallmark imaging sign used to diagnose MS and ...

For decades, clinicians treating multiple sclerosis (MS) have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging (MRI) scans as a sign that a patient’s disease ...

Multiple sclerosis, a complex neurological condition affecting nearly 3 million people worldwide, has long been characterized by its elusiveness. Even as medical imaging technology has advanced ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

The investigational drug tolebrutinib effectively reduces brain lesions in patients with highly active relapsing-remitting multiple sclerosis (RRMS), new research suggests. After 12 weeks of treatment ...

Roche RHHBY announced new data from the mid-stage study on an experimental candidate, fenebrutinib, for treating relapsing multiple sclerosis (“RMS”). Fenebrutinib is an investigational oral, ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial by reducing brain lesions in adults with relapsing forms of multiple sclerosis ...

FILE PHOTO: Logo of Swiss drugmaker Roche is seen in Basel FRANKFURT (Reuters) - Roche said on Wednesday that its multiple sclerosis drug candidate, part of a class of compounds that has been linked ...

BUFFALO, N.Y. — For decades, clinicians treating multiple sclerosis (MS) have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging (MRI) scans as a sign that a ...